德国默克终止bintrafusp alfa的肺癌三期

即便有梁静茹的勇气，也不能根据一个小样本的Ph1就贸然开三期

前事不忘，后事之师。。。

Merck KGaA discontinues anti-PD-L1/TGF-beta trap (bintrafusp alfa) in NSCLC

the study is unlikely to meet the primary efficacy endpoint.

Merck KGaA / Key word(s): Study/Study results

Merck KGaA: Merck KGaA to discontinue bintrafusp alfa clinical trial (INTR@PID Lung 037)

20-Jan-2021 / 13:30 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

Merck KGaA (the "Company") is investigating a bifunctional immunotherapy, bintrafusp alfa (anti-PD-L1/TGF-beta trap), as a potential therapy for difficult to treat cancers.

While reviewing the totality of data from the ongoing clinical trial INTR@PID Lung 037 in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC) that have high expression of PD-L1 (the "Clinical Trial"), the Independent Data Monitoring Committee recommended on January 19, 2021 to discontinue the Clinical Trial. Based on this recommendation, the Company has made the decision to discontinue the Clinical Trial, as the

study is unlikely to meet the primary efficacy endpoint. The recommendation by the Independent Data Monitoring Committee and the Company's decision is related only to this Clinical Trial.

Bintrafusp alfa is currently under clinical investigation and not approved for any use anywhere in the world.

后面也没什么意义了吧

有时候预感还是挺准的：ESMO20的时候

Bintrafusp alfa update 的时候已经是不良的预感

所以以后谁再拿个single arm的ORR来说事且不提供相应的biomarker analysis，把伊当sb好了，梁静茹的勇气也不敢这么唱

另外也不能一锤子打死TGFb，因为avelumab本身就很烂嘛，之前最担心的，大家把锅一股脑的扣到TGFb而忽略了avelumab

后续提供详细更新